Ankit Mangla, MD published a study on optimal neoadjuvant therapy for patients with high-risk resectable melanoma. Despite the potential benefits, there hasn't been a clear optimal regimen until now. Learn how this can lead to more personalized treatment: tinyurl.com/4jcc59nt

Excited to publish our 1st paper in ESMO Gastrointestinal Oncology. Liquid biopsy is knocking at the door!!! ESMO - Eur. Oncology Florian Lordick Ducreux Michel Leslie Bucheit Dr Amit Mahipal Keelia Clemens Aditya Shreenivas MD MS University Hospitals Pashtoon Kasi MD, MS

A nice contribution of ⁦McGill_Sarcoma⁩ group to the literature on myxoid liposarcoma. Definitely, in my experience, whole-body MRI made a difference. Happy to see our publication come through. link.springer.com/article/10.100…

PD1 vs Dual IO in Neoadjuvant #melanoma ?? @esmo news highlights our analysis of the #neoadjuvant trials in resectable #melanoma . Exciting to see the global impact of our paper. ChanMi Lee UH Research & Education Institute
Case Comp Cancer Ctr jamanetwork.com/journals/jamao…
Read here ☝🏽 & 👇🏽 esmo.org/oncology-news/…

Join us in person or via livestream on Friday, April 19, for the Adamczyk Lecture presented in partnership with CWRU Biomedical Engineering, “Radiomics, Radiogenomics, and AI: The Emerging Role of Imaging Biomarkers in Precision Cancer Care” with Despina Kontos.

#Neoadjuvant therapy for #melanoma is the new kid on the block. Our analysis provides guidance on the choice of regimen. Read on! jamanetwork.com/journals/jamao…
Doctors Weigh Patient Goals Instead of ‘Dictating’ Melanoma Treatment curetoday.com/view/doctors-w… via CURE Today

Ankit Mangla, MD of CWRU School of Medicine spoke with CURE® about discussions patients with #Melanoma and doctors should have regarding preferred outcomes with treatment.

Read the article here: curetoday.com/view/doctors-w…

Accelerated approval is critical to get access to the drug & third-party coverage. OS is a complex endpoint today due to non-chemo options that can alter the tumor environment, making it difficult to predict response. I wud still bat for accelerated approval.

Most viewed in the last 7 days from JAMA Oncology:

What is the optimal neoadjuvant regimen for patients with operable node-positive, high-risk stage III and IV melanoma?

ja.ma/4cLDqEK

An honor to have been invited to write the following editorial accompanying this article. Thanks to JAMA Oncology

jamanetwork.com/journals/jamao…

It's finally out... almost 2 years later since its conception 🙊🙊. My biggest thank you to Cassandra Calabrese and Cassandra Calabrese for letting me take the lead. Thank you for your amazing mentorship!!

Evidence-Based Integrative Oncology Approaches Forge a New Path in Cancer Care. City of Hope #oncology #integratvieoncology
onclive.com/view/evidence-…

A nice review of our recent paper published in JAMA Oncology discussing the optimal regimen in the #neoadjuvant setting for #melanoma . jamanetwork.com/journals/jamao….
Read on! Case Comp Cancer Ctr
ajmc.com/view/review-ne…

Thank you for YOUR mentorship too, Dr. Mangla, for us trainees! 🫡 And congratulations team - Finally!!! 🥳🥳🥳🎉🎉🎉🎉

Intriguing & exciting data. WDLPS & DDLPS can coexist within the same tumor. Waiting for full paper to understand how one can determine the lack of or existence of DDLPS within WDLPS preoperatively? Does this knowledge even make a difference? TARPSWG John Ammori Luke D. Rothermel